• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Immunome Reports Full Year 2024 Financial Results and Provides Business Update

    3/19/25 4:05:00 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNM alert in real time by email
    • Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025.
    • First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC.
    • IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy.
    • Projected cash runway extends into 2027

    Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update.

    "Immunome's efficient execution in 2024 laid the foundation for a productive 2025," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "We are pleased with the progress of our pipeline and, with multiple programs now in clinical development, we expect that our recent financing will support multiple clinical milestones. We particularly look forward to topline data in the second half of 2025 for the RINGSIDE trial of varegacestat, which we believe will demonstrate significant benefits for patients with desmoid tumors.

    "Our highly capable team is achieving our vision of a broad, differentiated portfolio of ADCs. We recently dosed the first patient in the Phase 1 clinical trial of IM-1021, our ROR1-targeted ADC. Three additional novel ADCs, IM-1617, IM-1335 and IM-1340, are in IND-enabling manufacturing, with additional discovery-stage programs under evaluation. We recently submitted the IND for IM-3050, our FAP radiotherapy, and anticipate initiating a Phase 1 clinical trial for that program later this year."

    Pipeline Highlights

    Varegacestat: Full enrollment for the Phase 3 RINGSIDE Part B study of varegacestat for the treatment of desmoid tumors was completed in February 2024, and Immunome expects to report topline data for RINGSIDE Part B in the second half of 2025. In parallel, Immunome is performing the manufacturing and pharmacology work required to support a new drug application filing for varegacestat.

    IM-1021: The Phase 1 clinical trial of IM-1021 is ongoing, with the first patient dosed in February 2025. The Phase 1 trial is an open-label, multicenter dose-escalation and expansion study that is expected to include participants with advanced B-cell lymphomas and advanced solid tumors.

    IM-3050: Immunome recently submitted an IND for IM-3050 and expects to initiate a clinical trial for the program in the second half of 2025.

    Preclinical Pipeline – Immunome's preclinical pipeline also includes three novel ADCs against solid tumor targets, IM-1617, IM-1340 and IM-1335, which are currently undergoing IND-enabling work, and additional, undisclosed ADCs in discovery and lead optimization.

    Fourth Quarter and Recent Corporate Highlights

    • Successfully completed an upsized underwritten public offering for gross proceeds of $172.5 million in January 2025, providing capital that is expected to support achievement of clinical milestones for varegacestat, IM-1021 and IM-3050 and the advancement Immunome's preclinical pipeline.
    • Nominated IM-1617, IM-1340 and IM-1335 as novel ADC candidates, with IND-enabling work initiated in late 2024.
    • Presented data highlighting preclinical efficacy for IM-1021 and a differentiated profile for HC74, Immunome's proprietary TOP1 ADC payload, at the 36th ORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October 2024.

    Full-year 2024 Financial Results

    • As of December 31, 2024, cash, cash equivalents and marketable securities totaled $217.3 million, which does not include gross proceeds of $172.5 million from the January 2025 financing. Immunome's current cash runway is expected to extend into 2027.
    • Research and development expenses for the year ended December 31, 2024 were $129.5 million, including stock-based compensation costs of $5.1 million.
    • In-process research and development expenses for the year ended December 31, 2024 were $152.3 million. These expenses were related to Immunome's business development activity.
    • General and administrative expenses for the year ended December 31, 2024 were $33.0 million, including stock-based compensation expense of $10.6 million.
    • Immunome reported a net loss of $293.0 million for the year ended December 31, 2024.

    About Immunome, Inc.

    Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which is the subject of a recently submitted IND. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit www.immunome.com.

    Cautionary Statement Regarding Forward-Looking Statements

    Statements in this press release that are not purely historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as "expect," "foundation," "look forward," "believe," "vision," "anticipates" and similar expressions to identify these forward-looking statements. These forward-looking statements include Immunome's expected timing for providing topline data for the Phase 3 RINGSIDE Part B trial; Immunome's expected cash runway and ability to achieve clinical milestones; Immunome's expectation that it will enroll patients in its Phase 1 clinical trial for IM-1021 and will report resulting clinical trial data, and that it will initiate a Phase 1 clinical trial for IM-3050; Immunome's expectations regarding regulatory filings; the ability of Immunome to advance its pipeline; the potential of Immunome's ADC programs to provide first-in-class or best-in-class status; and other statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future. These forward-looking statements are based on Immunome's current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including the risk that Immunome will not be able to realize the benefits of its strategic transactions; the risk that regulatory approvals for Immunome's programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions; the risk that pre-clinical data may not be predictive of clinical data; the risk that Immunome's programs and product candidates fail to achieve their intended endpoints; uncertainties related to Immunome's capital requirements and Immunome's expected cash runway; Immunome's ability to grow and advance its pipeline and successfully execute on its business plan; and other risks and uncertainties indicated from time to time described in Immunome's Annual Report on Form 10-K for the year ended December 30, 2024 being filed with the SEC today, and in Immunome's other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.

    IMMUNOME, INC.
    Consolidated Balance Sheets
    (In thousands)
    December 31, 2024 December 31, 2023
    Assets
    Current assets:
    Cash and cash equivalents $

    143,351

     

    $

    98,679

     

    Marketable securities

    73,952

     

    39,463

     

    Prepaid expenses and other current assets

    4,036

     

    6,561

     

    Total current assets

    221,339

     

    144,703

     

    Property and equipment, net

    10,113

     

    2,073

     

    Operating right-of-use assets

    4,278

     

    1,564

     

    Restricted cash

    100

     

    100

     

    Other long-term assets

    4,411

     

    100

     

    Total assets $

    240,241

     

    $

    148,540

     

    Liabilities and stockholders' equity
    Current liabilities:
    Accounts payable $

    14,189

     

    $

    3,311

     

    Accrued expenses and other current liabilities

    33,177

     

    8,025

     

    Deferred revenue, current

    6,941

     

    10,493

     

    Total current liabilities

    54,307

     

    21,829

     

    Deferred revenue, non-current

    —

     

    5,489

     

    Operating lease liabilities, net of current portion

    4,769

     

    1,340

     

    Total liabilities

    59,076

     

    28,658

     

    Stockholders' equity:
    Preferred stock

    —

     

    —

     

    Common stock

    6

     

    4

     

    Additional paid-in capital

    696,872

     

    342,663

     

    Accumulated other comprehensive income

    57

     

    22

     

    Accumulated deficit

    (515,770

    )

    (222,807

    )

    Total stockholders' equity

    181,165

     

    119,882

     

    Total liabilities and stockholders' equity $

    240,241

     

    $

    148,540

     

    IMMUNOME, INC.
    Consolidated Statements of Operations and Comprehensive Loss
    (In thousands, except share and per share amounts)
     
    Year Ended December 31,

    2024

    2023

    Collaboration revenue $

    9,041

     

    $

    14,018

     

    Operating expenses:
    In-process research and development

    152,344

     

    80,802

     

    Research and development(1)

    129,542

     

    23,089

     

    General and administrative(1)

    32,955

     

    19,657

     

    Total operating expenses

    314,841

     

    123,548

     

    Loss from operations

    (305,800

    )

    (109,530

    )

    Interest income

    12,837

     

    2,724

     

    Net loss $

    (292,963

    )

    $

    (106,806

    )

    Net loss per share, basic and diluted $

    (5.00

    )

    $

    (5.38

    )

    Weighted-average shares outstanding, basic and diluted

    58,639,441

     

    19,843,651

     

    Comprehensive loss
    Net loss $

    (292,963

    )

    $

    (106,806

    )

    Unrealized gain on marketable securities

    35

     

    22

     

    Comprehensive loss $

    (292,928

    )

    $

    (106,784

    )

     
    (1) Amounts include non-cash stock-based compensation as follows (in thousands):
     
    Year Ended December 31,

    2024

    2023

    Research and development $

    5,146

     

    $

    1,981

     

    General and administrative

    10,602

     

    4,242

     

    Total share-based compensation expense $

    15,748

     

    $

    6,223

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250319932146/en/

    Investor Contact:

    Max Rosett

    Chief Financial Officer

    [email protected]

    Get the next $IMNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMNM

    DatePrice TargetRatingAnalyst
    4/2/2025$23.00Buy
    Lake Street
    11/8/2024$30.00Overweight
    Stephens
    5/31/2024$27.00Overweight
    Piper Sandler
    4/30/2024$24.00Overweight
    JP Morgan
    4/15/2024$35.00Buy
    Guggenheim
    1/29/2024$30.00Outperform
    Leerink Partners
    12/19/2023$12.00Outperform
    Wedbush
    10/29/2021$35.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $IMNM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bienaime Jean Jacques bought $60,684 worth of shares (7,800 units at $7.78), increasing direct ownership by 33% to 31,415 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:05:21 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Siegall Clay B bought $999,459 worth of shares (137,100 units at $7.29), increasing direct ownership by 20% to 806,736 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:03:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bienaime Jean Jacques bought $57,470 worth of shares (7,000 units at $8.21), increasing direct ownership by 42% to 23,615 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/25/25 5:18:02 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunome Inc.

      SC 13G/A - Immunome Inc. (0001472012) (Subject)

      11/14/24 9:00:58 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Immunome Inc.

      SC 13G - Immunome Inc. (0001472012) (Subject)

      11/14/24 1:28:33 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Immunome Inc.

      SC 13G - Immunome Inc. (0001472012) (Subject)

      11/14/24 10:33:51 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Immunome with a new price target

      Lake Street initiated coverage of Immunome with a rating of Buy and set a new price target of $23.00

      4/2/25 8:05:05 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Immunome with a new price target

      Stephens initiated coverage of Immunome with a rating of Overweight and set a new price target of $30.00

      11/8/24 8:17:18 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Immunome with a new price target

      Piper Sandler initiated coverage of Immunome with a rating of Overweight and set a new price target of $27.00

      5/31/24 7:43:20 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Financials

    Live finance-specific insights

    See more
    • Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

      Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th

      3/28/24 4:02:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Third Quarter 2023 Financial Results

      - Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors - - Cash runway expected to extend into Q1 2026* - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

      11/9/23 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Fourth Quarter and Full Year 2022 Financial Results

      Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. "Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our p

      3/16/23 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 164,500 shares of common stock to nine new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $8.8

      5/2/25 4:01:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first

      4/4/25 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 228,000 shares of common stock to five new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $6

      4/3/25 4:05:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Higgins Jack exercised 5,200 shares at a strike of $1.35, increasing direct ownership by 38% to 18,729 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/28/25 5:54:02 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bienaime Jean Jacques bought $60,684 worth of shares (7,800 units at $7.78), increasing direct ownership by 33% to 31,415 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:05:21 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Siegall Clay B bought $999,459 worth of shares (137,100 units at $7.29), increasing direct ownership by 20% to 806,736 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:03:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

      Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant

      2/11/25 8:30:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Appoints Roee Shahar as Executive Vice President, Commercial

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.

      10/8/24 8:05:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

      Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board of Directors. Dr. Sarma, who will hold the title of Executive Chairman, will actively support the strategic development of STALICLA, working closely with the CEO, Lynn Durham, and the management team. With an

      7/9/24 7:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Immunome Inc.

      DEFA14A - Immunome Inc. (0001472012) (Filer)

      4/24/25 4:07:28 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Immunome Inc.

      DEF 14A - Immunome Inc. (0001472012) (Filer)

      4/24/25 4:05:30 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Immunome Inc.

      S-8 - Immunome Inc. (0001472012) (Filer)

      3/19/25 5:10:27 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care